Advanced screening panel using liquid biopsy and specialized blood markers to detect early biological signals associated with cancer development, often before symptoms appear.

Analyzes microscopic material released by cells into the bloodstream. It evaluates circulating tumor DNA (ctDNA) for abnormal fragments, cell-free DNA (cfDNA) for cellular damage insights, and circulating tumor cells (CTCs) to detect rare cells that may break away from tumors.
Analyzes proteins sometimes associated with cancers. CA 19-9 is linked to pancreatic and gastrointestinal activity, while expanded CEA helps detect abnormal activity tied to colorectal, lung, and other cancer types.